BioCentury | Apr 17, 2021
Deals

April 16 Quick Takes: AZ’s $39B Alexion deal clears FTC hurdle; plus Biosplice, C2i, Relay, Surrozen and more

...University of Minnesota and exclusively licensed by Qlaris, is a prodrug of levcromakalim, an ATP-sensitive potassium channel...
BioCentury | Apr 16, 2021
Targets & Mechanisms

New targets featured at AACR signal growing opportunity in established mechanisms

The bulk of the new targets presented at AACR21 involve pathways and mechanisms active in tumor cells rather than immune cells, reflecting the biotech industry’s growing interest in targeted oncology and...
BioCentury | Mar 31, 2021
Regulation

March 31 Quick Takes: Basket of EU approvals includes MS, SMA drugs; plus Amarin, AbbVie, Cara-Vifor

The European Commission approved Kesimpta ofatumumab from Novartis AG (NYSE:NVS; SIX:NOVN) to treat relapsing forms of multiple sclerosis. The subcutaneously administered drug was originally developed by Genmab A/S (CSE:GMAB; NASDAQ:GMAB). Evrysdi risdiplam, an oral small molecule...
BioCentury | Mar 27, 2021
Product Development

What it will take to meet CEPI’s 100-day vaccine goal for the next pandemic

As CEPI looks to prepare for the next pandemic, it has set a lofty goal to reduce to 100 days the time from sequencing the pathogen to a regulatory submission of a vaccine. But meeting...
BioCentury | Mar 16, 2021
Product Development

March 16 COVID Quick Takes: FDA launches adverse events dashboard; plus Kintor, Boehringer, Apeiron, Moderna and more

FDA launched an FDA Adverse Event Reporting System (FAERS) public dashboard for COVID-19 drugs and biologics with emergency use authorization (EUA). The launch comes as EMA’s Pharmacovigilance Risk Assessment...
BioCentury | Mar 13, 2021
Product Development

Long COVID therapies are starting to populate a sparse pipeline

As Long COVID research ramps up, the first set of therapeutic candidates are either geared toward organ-centered pathology shared with other diseases, or viral and immune mechanisms that could be unifying...
BioCentury | Mar 13, 2021
Translation in Brief

NIH identifies antisense oligos to treat progeria; plus epigenetic gene therapies for chronic pain and Cend’s pancreatic cancer therapy

Antisense oligonucleotides to treat progeriaTwo NIH teams, one led by NIH director Francis Collins, discovered antisense oligonucleotides (ASOs) against the LMNA gene to treat Hutchinson-Gilford progeria syndrome (HGPS). The disorder is caused by progerin, a...
BioCentury | Mar 13, 2021
Finance

March 12 Quick Takes: Longboard, Prometheus rise after pricing IPOs; plus Monte Rosa, Nano Cures and CalciMedica

A pair of newly public NASDAQ companies traded up on Friday. Prometheus Biosciences Inc. (NASDAQ:RXDX), which raised $190 million in an upsized IPO, rose 33% to $25.29. The GI company raised $130 million in a November...
BioCentury | Mar 2, 2021
Product Development

March 2 Quick Takes: Merck to help manufacture J&J COVID vaccine; plus EMA, Neurocrine, and FDA reviews for Merck, Avadel and argenx

At a White House press briefing Tuesday, President Joe Biden said Merck & Co. Inc. (NYSE:MRK), with aid from the Defense Production Act, will help manufacture COVID-19 Vaccine Janssen from Johnson & Johnson (NYSE:JNJ). FDA...
BioCentury | Feb 18, 2021
Politics, Policy & Law

Biden testing pilot kicks off U.S. catch-up on viral genomic surveillance

The first $1.7 billion spent in the Biden administration’s $50 billion testing plan includes a down payment to boost the CDC’s genomic sequencing capacity threefold. The remainder will be channeled toward regional coordination of testing...
Items per page:
1 - 10 of 3291